FGEN - Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy
- Over 10 million people are stricken by cancer each year, with as much as 60% suffering from loss of appetite or anorexia and wasting disease or cachexia.
- With no standard of care available to treat patients with cancer-related anorexia, there is an eager patient population ready for an effective treatment.
- Phase Ia/Ib clinical trial of Artelo’s ART27.13 compound is fully enrolled and final data could be available for year-end 2022, providing proof of efficacy among cancer patients suffering from anorexia.
- Capital raise in late 2021 has provided sufficient capital resources to support Artelo through the completion of the required Phase II clinical trials for its ART27.13.
- Using potential competitors and peers with publicly traded stock to provide comparable valuation metrics, ARTL is found to have intrinsic value well above its current stock price.
For further details see:
Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy